<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39326212</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax®) by HIPRA.</ArticleTitle><Pagination><StartPage>126386</StartPage><MedlinePgn>126386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126386</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01068-5</ELocationID><Abstract><AbstractText>SARS-CoV-2 virus variants continue to emerge at an alarming rate due to spontaneous genetic mutations, particularly in the spike protein receptor-binding domain (RBD) portion, which render the virus more likely to escape immunity. So far, the immunity obtained through global primary and/or booster immunisation campaigns has been sufficient to protect the population from new emerging variants of the Omicron lineage. The current approach to update vaccines' antigen composition to new variants to boost immunity may not be sustainable in the long term. It might also be potentially redundant if the mutations are giving rise to variants which induce milder infections and existing vaccines, such as Bimervax®, are still sufficiently protective, as Covid is slowly becoming a seasonal illness. Through measuring neutralising antibody titres in sera from subjects boosted with Bimervax®, we have demonstrated the ability of Bimervax® to induce immune responses against a variety of SARS-CoV-2 variants, ranging from earlier variants inducing more serious infections to more recent variants which have been found to produce milder infections.</AbstractText><CopyrightInformation>Crown Copyright © 2024. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>England</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency (UKHSA), Manor Farm Road, Porton, Salisbury SP4 0JG, United Kingdom. Electronic address: anna.england@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency (UKHSA), Manor Farm Road, Porton, Salisbury SP4 0JG, United Kingdom. Electronic address: julia.sung@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deulofeu</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HIPRA, Avenida La Selva, 135, 17170 Amer, (Girona), Spain. Electronic address: meritxell.deulofeu@hipra.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soler</LastName><ForeName>Laura Ferrer</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>HIPRA, Avenida La Selva, 135, 17170 Amer, (Girona), Spain. Electronic address: laura.ferrer@hipra.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallis</LastName><ForeName>Bassam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency (UKHSA), Manor Farm Road, Porton, Salisbury SP4 0JG, United Kingdom. Electronic address: bassam.hallis@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency (UKHSA), Manor Farm Road, Porton, Salisbury SP4 0JG, United Kingdom. Electronic address: kelly.thomas@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charlton</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency (UKHSA), Manor Farm Road, Porton, Salisbury SP4 0JG, United Kingdom. Electronic address: sue.charlton@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bimervax®</Keyword><Keyword MajorTopicYN="N">Neutralising antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Anna England reports was provided by UKHSA. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326212</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126386</ArticleId><ArticleId IdType="pii">S0264-410X(24)01068-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>